ONL Therapeutics Completes Enrollment in Global Phase 2 Trial for Geographic Atrophy Treatment
ONL Therapeutics, a clinical-stage biopharmaceutical company, has announced the completion of enrollment for its global Phase 2 GALAXY trial. The trial, which is evaluating the efficacy and safety of xelafaslatide (formerly ONL1204) for patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), has enrolled over 324 participants across sites in the U.S., Canada, and Europe. According to David N. Zacks, M.D., Ph.D., chief scientific officer at ONL Therapeutics, the rapid enrollment signifies a strong demand from physicians and patients for new treatment options for GA, an irreversible disease with limited approved therapies. Xelafaslatide is designed to protect retinal cells from Fas-mediated cell death, aiming to preserve vision with a potential dosing frequency of every three to six months. The GALAXY trial builds on positive data from a Phase 1b study, which indicated that xelafaslatide was generally safe and well-tolerated, showing encouraging efficacy signals afte...